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Objectives: Current health technology assessment (HTA) methods guidelines for medical devices may benefit from contributions by biomedical and clinical engineers. Our study aims
to: (i) review and identify gaps in the current HTA guidelines on medical devices, (ii) propose recommendations to optimize the impact of HTA for medical devices, and (iii) reach a
consensus among biomedical engineers on these recommendations.
Methods: A gray literature search of HTA agency Web sites for assessment methods guidelines on devices was conducted. The International Federation of Medical and Biological
Engineers (IFMBE) then convened a structured focus group, with experts from different fields, to identify potential gaps in the current HTA guidelines, and to develop
recommendations to fill these perceived gaps. The thirty recommendations generated from the focus group were circulated in a Delphi survey to eighty-five biomedical and clinical
engineers.
Results: Thirty-two panelists, from seventeen countries, participated in the Delphi survey. The responses showed a strong agreement on twenty-seven of thirty recommendations.
Some uncertainties remain about the methods to accurately assess the effectiveness and safety, and interoperability of a medical device with other devices or within the clinical
setting.
Conclusions: As medical devices differ from drug therapies, current HTA methods may not accurately reflect the conclusions of their assessment. Recommendations informed by the
focus group discussions and Delphi survey responses aimed to address the perceived gaps, and to provide a more integrated approach in medical device assessments in combining
engineering with other perspectives, such as clinical, economic, patient, human factors, ethical, and environmental.
Keywords: Medical device, Health technology assessment, Guidelines, Clinical and biomedical engineering
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The World Health Organization describes medical devices
(MDs) as essential tools for prevention, diagnosis and treatment
of illnesses and diseases, and patient rehabilitations (1). The
European Parliament and Council of the European Union
defines a MD as “any instrument, apparatus, appliance, soft-
ware, implant, reagent, material or other article intended by
the manufacturer to be used, alone or in combination, for
human beings” (2). Furthermore, they are used for different
purposes such as diagnosis, prevention, monitoring, prediction,
prognosis, treatment, alleviation, or compensation of disease,
injury, or disability (2). Moreover, the U.S. Food and Drug
Administration specifies that MDs are “intended to affect the
structure or any function of the body of man or other
animals, and which does not achieve any of its primary
intended purposes through chemical action within or on the
body of man or other animals and which is not dependent
upon being metabolized for the achievement of any of its
primary intended purposes” (3).
There are important differences between drug therapies and
medical devices. These differences can impact health technol-
ogy assessment (HTA) methods and can be grouped into five
categories: product lifecycle, clinical evaluation, user issues,
costs and economic evaluation, and intellectual property (4).
This diversity among drugs and MDs results in different assess-
ment needs, evaluation criteria, and approaches.
The perspective of clinical and biomedical engineers is par-
ticularly relevant in the assessment of MDs and, given the drug-
oriented development of HTAmethods and processes in the past
decades, it is unlikely to be addressed in many HTA guidelines
(5). SomeHTA agencies or networks have developed guidelines
specific to MDs and diagnostics (6–11) (Supplementary
Table 1).However, it remains uncertainwhether these guidelines
considered all the unique features ofMDs as relevant for the clin-
ical and biomedical engineers’ community.
In 2017, Schnell-Inderst et al. (12) developed recommenda-
tions for the planning and conduct of systematic reviews of
therapeutic MDs. A targeted literature review of methodo-
logical publications and guidelines on the design, conduct, ana-
lysis, and reporting of primary studies on the clinical evaluation
of therapeutic MDs and surgical procedures was performed
(12). The recommendations were based primarily on the infor-
mation from the literature review, judgement and experience of
the authors, and discussions with their project partners at
MedTech and the European Network for Health Technology
Assessment (EUnetHTA) (12). The authors highlighted the
necessity to define the intervention and describe the technical
characteristics and to identify and measure the potential effect
modifiers, such as the incremental development of the device,
the experience and learning curve of the user, and contextual
factors (12).
The involvement of biomedical and clinical engineers in
HTAcan provide insights on the technical characteristics, usabil-
ity, safety, user setting dependences, organizational impact, and
maintenance of devices throughout their lifecycle (13–15). In a
2013 study, Margotti et al. interviewed clinical engineers,
healthcare providers, and managers in four public hospitals in
Brazil to inquire about their perspectives on the decision
making process in acquiring new medical equipment, HTA,
and the identification of aspects to guide HTA in their institu-
tions. Based on the participants’ responses, the authors con-
cluded that the decision making process to introduce a new
medical equipment was not based on evidence, and therefore,
recommended that the hospitals should establish a formal HTA
process that would involve clinical engineers to integrate
medical equipment in the hospitals. The HTA process would
be separate from a technical evaluation for procurement
decisions (16).
In November 2016, as part of the 2015–18 HTA program,
the International Federation of Medical and Biological
Engineers (IFMBE)-HTA Division held a focus group to con-
textualize the differences between MDs and drugs and their
impact on HTA. The study objectives were to: (i) review and
identify the gaps in the current HTA guidelines on MDs; (ii)
propose recommendations (4) to improve the accuracy of MD
assessments and compare current HTA MD guidelines with
the proposed recommendations; and (iii) to reach a consensus
among clinical and biomedical engineers on the proposed
recommendations with a modified Delphi survey.
METHODS
We conducted a structured focus group to review and identify
the gaps in HTA guidelines for MDs, and we developed a modi-
fied Delphi survey to establish consensus within the community
of biomedical and clinical engineers on the recommendations
proposed to address the perceived gaps. The study received
full ethics approval by University of Warwick Ethical
BSREC Committee (REGO-2017-2072).
Focus Group
Health Technology Guidelines. Guidelines were obtained from a limited
gray literature search of HTA agency Web sites and from con-
tributions among the study investigators (7–11). They were
identified through a focused Internet search on HTA organiza-
tions and research initiatives up until May 2018. These searches
were supplemented by reviewing the bibliographies of the
guidelines and through contacts with appropriate experts and
manufacturers. HTA guidelines were selected for inclusion if
they were specific to any type of MD and described methods
to evaluate medical technology. Guidelines that presented
solely the clinical review methods, were focused on HTA pro-
cesses only, or were not explicit about the appropriate methods
for medical device assessments were excluded.
Six HTA guidelines (6–11), published from 2011 (7) to
2018 (10), were selected for inclusion in the review. A standar-
dized data extraction form was designed a priori to document
Polisena et al.
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and tabulate all relevant information from the included guide-
lines. One investigator (J.P.) extracted information for each
HTA component in the guidelines, and a second investigator
(R.C.) reviewed the extracted information. Another investigator
(L.P.) prepared a table to extract the relevant information from
the guidelines (17). Accordingly, the description of how HTA
guidelines addressed the product lifecycle, clinical evaluation,
user issues, and costs and economic evaluation for medical
devices were extracted.
A narrative summary of the HTA methods described in the
guidelines was performed. The methods described in the HTA
guidelines were contrasted with the proposed recommendations
developed by the focus group to determine which recommenda-
tions were addressed in full or partially in the existing guide-
lines and which ones were not addressed at all.
Focus Group Discussions. Fifteen members and collaborators of the
IFMBE were invited for a 2-day structured focus group
which was convened between November 26 and 27, 2016 at
the School of Engineering at the University of Warwick. A
second focus group was convened at the European Medical
and Biological Engineering and North-Baltic Conference on
Biomedical Engineering and Medical Conference on June 16,
2017, in Tampere, Finland, to finalize the recommendations.
Focus group participants comprised of: biomedical and clinical
engineers, human factors experts, health economists, and epide-
miologists, all with experience in HTAs. The focus group was
coordinated by the Chair of the IFMBE-HTA Division.
The aims of the focus group were to: (i) contextualize the
differences between MD and drugs in terms of their character-
istics and functionality (18;19); (ii) review and expand the list
of the main differences between MD and drugs that can
impact the HTA methods identified in previous studies (4);
and (iii) develop a set of recommendations to fill any identified
gap on HTA guidelines to assess MDs.
Using the narrative summary of the guidelines, the focus
group discussed and developed an initial set of recommenda-
tions. These initial recommendations were then mapped onto
the European Network for Health Technology Assessment
(EUnetHTA) (4) domains (i.e., health problem and current
use of the technology, description and technical characteristics
of technology, safety, clinical effectiveness, costs and economic
evaluation, ethical analysis, organizational aspects, patients,
social, and legal aspects).
Delphi Survey
Survey Design. The Delphi method is a process that uses a series of
rounds of questionnaires to gather information in a structured
manner until consensus is obtained (20). For our study, we con-
ducted an online Delphi survey. This approach enabled: (i) the
anonymity of each panelist; (ii) to reach panelists from various
geographic locations; and iii) to reduce the risk of one or more
panelists dominating the consensus process (20–22). The aim
of the Delphi process for the present study was to obtain con-
sensus from panelists with different perspectives and expertise,
and not to achieve statistical power (21). In particular, the
objective of the Delphi survey was to achieve consensus on
the 30 recommendations proposed by the focus group to fill
the perceived gaps in HTA process to evaluate MDs.
The online Delphi survey (Supplementary File 1) consisted
of a demographic section and a section to inquire about the pane-
list’s agreement level with the thirty recommendations proposed
by the focus group to enhance the HTA guidelines for MDs.
Before a wider distribution, the survey was piloted among a
handful of clinical and biomedical engineers to estimate the
time to complete the survey, and to review the flow of inter-
action, coherence, and appropriateness of format and contents.
Delphi Process. We invited a purposive sample of approximately 85
international professionals through an email invitation. The
panelists were identified through the IFMBE associates, study
investigators’ networks, and scientific and professional soci-
eties. They were selected based on their experience with
health technology assessments, including design, development,
testing, implementation, selection, procurement, reimburse-
ment, maintenance, and from various areas in the healthcare
sector.
Our email invitation included a letter inviting the individual
to participate, and described the study objectives, an overview
of the Delphi methods, expected time to complete survey, and a
link to the survey. The invitation also indicated that any infor-
mation provided would have been used in a publication. If the
participants were unable to participate in the Delphi process, we
invited them to suggest alternates, whom they believed would
have been appropriate for the study.
A 5-point Likert scale was applied, where “1” was strongly
disagree and “5”was strongly agree. Median scores were calcu-
lated per recommendation to characterize the answer category
above and below which 50 percent of the answers fall.
Interquartile ranges (IQRs) were used to represent the spread
of the data and to assess the level of consensus per recommen-
dation. Ratings with a median of≤ 2 (i.e., high level of dis-
agreement with the proposed recommendation) and a narrow
IQR (i.e., IQR range between 1 and 2) were considered to
have reached consensus on a strong disagreement. Those
with a median≥ 4 with an IQR between 4 and 5 were consid-
ered to have reached consensus on a strong agreement with the
proposed recommendation. In addition, the free text comments
were assessed, especially for ratings that seem to be equivocal
as they can provide some insights on the respondents’ thought
process (23).
As consensus (i.e., median≥ 4) was reached for all pro-
posed recommendations in Round 1, another round of Delphi
iterations was not conducted.
HTA methods guidelines for MDs
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RESULTS
Focus Group
Table 1 summarizes the output of the focus group in terms of
potential recommendations to improve HTA process to evaluate
MDs. The table presents the proposed recommendations and
their association with the EUnetHTA domains, the MD charac-
teristics and the impact of those characteristics for the applica-
tion of HTA methods. The results of the focus group
discussions were organized in four main MD characteristics:
product lifecycle, clinical evaluation, issues in use, costs and
economic evaluation.
Product Lifecycle. Compared with drug therapies, MDs usually have
a shorter lifecycle due to iterative innovations, and the facility
to overcome patient protections often results in previous gen-
erations of devices to become obsolete. One direct consequence
of a shorter product lifecycle is that the evaluation of MDs at
market launch usually relies on limited evidence to measure
their safety, efficacy, effectiveness, and value for money.
Additional items related to the medical device lifecycle
include the maintenance required, potential instability of indi-
vidual parts that can impact the overall performance of the
device, and possible interferences with or dependency on
other devices. A lack of consideration for any of these items
can result in a risk of inaccurate estimates related to the efficacy,
effectiveness, safety, and cost-effectiveness of the device. Some
recommendations proposed to help address these perceived
gaps include obtaining as much data as feasible to more accur-
ately predict the medical device lifespan, using appropriate stat-
istical methods to analyze the different types of evidence,
understanding the maintenance requirements with validated
tools (e.g., ISO and IEC standards), and conducting risk assess-
ments and technical analyses of the minimum requirements for
possible interferences with other medical devices (Table 1).
Clinical Evaluation. The use of MDs involves a longer learning curve
if the design is more complex; thus, impacting the estimation of
the clinical efficacy and effectiveness, safety, cost-effective-
ness, and service provision of the device. To help ensure the
accuracy of the estimates, it is suggested to use both pre- and
postmarket and registry data that capture the impact of the
learning curve on outcomes, ensure that device users receive
appropriate training to reduce the risk of bias in measuring clin-
ical efficacy and effectiveness, and apply appropriate statistical
methods to incorporate the impact of the learning curve into the
estimates of outcomes and costs (Table 1).
Issues in Use. Most of the guidelines reviewed did not provide
any recommendations on how to identify and assess the
technical requirements and logistics, setting, and training,
and accreditation considerations for the user. The NICE-DAP
(6) mentioned that in some instances special implementation
issues and recommendations for use of a diagnostic test were
identified in their reports and Health Quality Ontario (HQO)
considers policies or legislation that can impact the implemen-
tation of the health technology in their jurisdiction (10). The
recommendations in Table 1 indicate the need for learning
curve estimations and the collection of data that reflect the
setting in which the MD will be used.
Costs and Economic Evaluation. Most guidelines discussed costs and
economic evaluations. The EUnetHTA guidelines focused on
the methods to assess the relative clinical effectiveness of thera-
peutic medical devices, but did not discuss cost-effectiveness
and other non-clinical benefits or harms (8). In addition to
primary economic evaluations, HQO also indicated that a
budget impact analyses may be included in their HTA
reports, and they conduct systematic reviews of the economic
evidence for the health technology (10).
Costs associated with the supply, installation, training of
users, supply of consumables, maintenance, and ongoing facil-
ities are important considerations to appropriately evaluate the
budget impact and cost-effectiveness of an MD. Compared with
drugs, different purchasing methods and financial schemes may
be available to the payers willing to adopt a new medical
device. For example, manufacturers may offer to supply infu-
sion devices free of charge to a hospital provided that they
also contract to purchase a given volume of giving sets. Such
arrangements are often referred to as “consumables deals.”
As well, hospitals use different ways to consolidate their
purchasing demand, sometimes at the interdepartmental,
inter-organizational, or system level. In European and other
countries, most highly innovative MDs are reimbursed
through diagnosis-related group–based payment systems,
which cover expenditures of hospital providers and encourage
lowering costs. Long-term tenders that procure large quantities
of specific products are common and facilitate interaction with
the suppliers while allowing clinicians to gain experience with
the devices; however, short-term targeted contracts are also
used in practice (24,25).
Considerations of such schemes are relevant when conduct-
ing an economic evaluation (26). The proposed recommenda-
tions suggest incorporating all operation costs and the
appropriate financial model to acquire the device in economic
evaluations and budget impact analyses. The operating costs
will be different for single-use devices.
The focus group prepared a list for each of the identified ten
gaps in the HTA guidelines on medical devices. These recom-
mendations and associated gaps were used then to develop the
Delphi survey (Supplementary File 1).
Delphi Survey
Characteristics of Panelists. We invited eighty-five professionals to par-
ticipate in the study, and thirty-two completed the survey (37.6
Polisena et al.
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Table 1. MD Characteristics and Functionality, Impact on HTA Methods, Proposed Recommendations for HTA Guidelines, and Associated EUnetHTA Domains
MD characteristic and
functionality Impact on HTA methods Proposed recommendations for HTA methods guidelines for medical devices Associated EUnetHTA domains
Product lifecycle
• Shorter lifecycle than drugs • Shorter timeframe for HTA completion
• Limited evidence available
• Estimates of cost-recovery may be inaccurate in the
cost-effectiveness analyses
• Obtain as much data as feasible to more accurately predict the MD
lifespan
• Use appropriate statistical methods (e.g., Bayesian methods) to analyze
the different types of evidence on the effectiveness and safety of the MD
• Conduct sensitivity analyses in economic model to measure the impact on
the results of varying lifespans
• Description and technical characteristics of
technology (TEC)
• Costs and economic evaluation (ECO)
• Organizational aspects (ORG)
• Maintenance required • Maintenance may impact costs, efﬁcacy, effectiveness,
satisfaction, and safety of the MD over its lifespan.
• Obtain additional insights about maintenance required
• Use any of the following tools to further understand device maintenance
requirements:
◦ Domain analysi
◦ User proﬁle, stakeholder identiﬁcation and analysi
◦ Usability (e.g., ISO 9241-11:1998)(37)
◦ Stakeholders (including patient and clinicians) experience (e.g. ISO
9241-210: 2010)(38)
◦ IEC standards (e.g., costs, downtime, etc.)
◦ Meantime between failures calculations
• Description and technical characteristics of
technology (TEC)
• Costs and economic evaluation (ECO)
• Organizational aspects (ORG)
• Safety (SAF)
• Clinical Effectiveness (EFF)
• Potential instability of indi-
vidual parts (e.g. software)
• Risk of inaccurate data and device failure may impact
safety, efﬁcacy, effectiveness, and cost-effectiveness
• Consider conducting a risk assessment
• Use appropriate and validated tool or standards to conduct a risk
assessment (e.g., ISO 14971, IEC/TR 80002-1: 2009 MD software
(39), etc.).
• If feasible, conduct a simulation of use to empirically analyze the safety
the device and deﬁne the processes of risk reporting , and to mitigate
residual risks (e.g., ISO 62336-1 2015)
• Costs and economic evaluation (ECO)
• Organizational aspects (ORG)
• Safety (SAF)
• Clinical Effectiveness (EFF)
• Possible interferences with
other MDs (e.g.,
radiofrequency)
• There may be minimum requirements in terms of
organization (e.g. personnel), technology
(e.g. radiofrequency interferences) and structure (e.g.,
physical spaces)
• Data exchange and interoperability
• Understand the setting and map the process of the device use
• Increase health professionals and patient awareness of such possible
interferences
• Manage and ensure processes of data exchange and interoperability of
the device within the health care setting and with other devices
• Conduct a technical analysis of and indicate the minimum requirements to
address possible interferences with other MDs (e.g., IEC 60601-1-2:
2001(40) compliant)
• Organizational aspects (ORG)
• Possible dependency on
other MDs
• Risk of inaccurate data if other devices fail or are
ineffective (e.g., working sub-optimally)
• Understand the setting and map the process of the device use
• Conduct a risk assessment to Identify and assess level of dependency on
other devices
• Clinical Effectiveness (EFF)
• Costs and economic evaluation (ECO)
HTA
methodsguidelinesforMDs
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Table 1. Continued
MD characteristic and
functionality Impact on HTA methods Proposed recommendations for HTA methods guidelines for medical devices Associated EUnetHTA domains
Clinical evaluation
• Longer learning curve • Impact on the estimation of efﬁcacy, effectiveness,
user satisfaction, safety, cost-effectiveness, and service
provision
• Use both pre-market (e.g., usability and risk assessment of the device
use; ISO 62336-1 2015) and post-market data to capture impact of
learning curve on outcomes
• Collect and report data on the effects of learning on relevant procedural
and clinical outcomes during clinical trials, both at the physician and centre
levels
• Collect registry data that allow the estimation of the learning curve based
on routine use of the MD once it has been adopted in clinical practice
• Ensure that device users enrolled in a trial have received appropriate
material for the device use (guidelines and service process of use) and
training to reduce the risk of bias in measuring clinical efﬁcacy and
effectiveness
• Use appropriate statistical methods to incorporate the learning curve into
the measurement of relevant outcomes and costs
• Costs and economic evaluation (ECO)
• Organizational aspects (ORG)
• Safety (SAF)
• Clinical Effectiveness (EFF)
• Designing a randomised
control trial (RCT) for a MD
is more challenging than
for drugs
• Blinding is a challenge in a study with MDs.
• Unlike drugs, MDs are diagnostic and therapeutic, and
they can inﬂuence the clinical decision making process
and the patient’s clinical care pathway.
• Adopt appropriate study designs for MDs. The design can include pre-
liminary phases of clinical pathway mapping and qualitative analysis to
identify the most appropriated setting, comparators and variables to be
considered in a trial.
• Reinforce the use of simulation in case of incremental innovation
• See above (i.e., longer learning curve)
Issues in use
• Performance is stronger
dependent on user and
context of use
• See above (i.e., learning curve)
• Efﬁcacy and effectiveness, satisfaction (i.e., usability)
are also dependent on user workload, stress level,
etc… The performance in the use of a device is a
context dependent factor. In this instance, the context
is deﬁned as “users, tasks, equipment (hardware,
software and materials), and the physical and social
environments in which a product is use”; ISO 9241-
11:1998)(37)
• See above (i.e., longer learning curve)
• Identify the setting and collect data on outcomes in the user training
phase
• See above (i.e., longer learning curve)
• Often requires intensive
training
• See above (i.e., learning curve) • See above (i.e., longer learning curve)
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percent) (Table 2). Between one to three panelists did not
provide scores for several recommendations.
Panelist characteristics are presented in Table 2, they repre-
sented seventeen countries. They ranged from five panelists
from Mexico (15.6 percent) to one each from Belgium, Chile,
China, Cuba, Ecuador, Egypt, Italy, the Netherlands, Spain,
and the United Kingdom. Over 25 percent of panelists were
clinical engineers (n= 12; 37.5 percent) or managers (n= 9;
28.1 percent). Almost 70 percent completed graduate studies
(masters: n= 10; 31.1 percent and doctorate: n= 12; 37.5
percent), and approximately 85 percent had 11 years or more
of service. The majority of respondents were involved in
HTA (n= 22; 68.8 percent) or health technology management
(n= 18; 56.3 percent), and over 20 percent indicated an acute
hospital (n= 8; 25 percent) or university (n= 7; 21.9
percent) as their principal employer.
Consensus on Recommendations. The median, the IQR, and the number
of panelists for each recommendation are presented in Table 3.
In Round 1, most of the recommendations reached a con-
sensus with a strong agreement (i.e., median≥ 4 and IQR
between 4 and 5). Two recommendations on the application
of sensitivity analyses in economic models to assess the
impact on the results of varying lifespans or incremental inno-
vations and the processes of data exchange and on the inter-
operability of the device within the hospital system or with
other devices had a median≥ 4, but the IQR was between 3
and 5. As well, one recommendation centered on the appropri-
ate methods to assess the evidence on medical device effective-
ness and safety presented a median equal to 4, but with an IQR
between 3 and 4.
Although the panelists agreed with the proposed recom-
mendations, several commented on their feasibility based on
the availability of high-quality evidence and questioned
whether existing statistical methods and economic models
used in HTAs can accurately assess the effectiveness and
safety of more complex health technologies. In addition, there
was some uncertainty on whether an HTA is the appropriate
approach to evaluate the interoperability of a MD with other
devices or within the hospital system and if a more technical
assessment conducted by entities with technical expertise is
warranted.
DISCUSSION
This study aimed to reach a consensus via an online Delphi
survey on recommendations proposed by the IFMBE-HTA
Division to address the perceived gaps in current HTA
methods guidelines for MDs. The thirty-two participants were
experts with numerous years of experience in the field of
HTA or health technology management in an academic hospital
or university.Ta
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Consensus with a strong agreement was achieved in the
first round for 90 percent (27/30) of the recommendations
related to the product lifecycle, clinical evaluation, issues in
use, and costs and economic evaluations. For the remaining
recommendations, consensus was reached but the IQR was
wider (e.g., 3 to 5). Comments indicated that panelists were
uncertain about the feasibility of accurately measuring the
effectiveness and safety of a medical device throughout the
product lifecycle given the available evidence and existing
statistical methods and economic models used in HTAs.
Furthermore, the appropriateness of an HTA to assess the inter-
operability of a medical device with other devices or within a
hospital system was questioned and a more technical assess-
ment was proposed instead.
Unlike drugs, the permission to market MDs may not be
based solely on the evaluation of efficacy and safety data
from randomized clinical trials. Although manufacturers must
perform clinical studies on human subjects for devices
labeled as high risk by the regulators, there are no explicit stan-
dards on the sample size, design, or follow-up period required
(27–29). Panelists in the Delphi survey commented that to
accurately assess the effectiveness and safety of MDs, more
appropriate evidence is required as well as the need for relevant
statistical and economic methods to measure the outcomes.
Both participants in the focus group and the survey agree
that similar to drug therapies, postmarket surveillance, and
observational data are complementary to the premarket
Table 2. Characteristics of Panelists (N= 32)
Characteristic Description Frequency (%)
Geographic location Argentina 3 (9.4)
Belgium 1 (3.1)
Brazil 4 (12.5)
Canada 4 (12.5)
Chile 1 (3.1)
China 1 (3.1)
Columbia 2 (6.3)
Cuba 1 (3.1)
Czech Republic 2 (6.3)
Ecuador 1 (3.1)
Egypt 1 (3.1)
Italy 1 (3.1)
Mexico 5 (15.6)
Netherlands 1 (3.1)
South Africa 2 (6.3)
Spain 1 (3.1)
United Kingdom 1 (3.1)
Professiona Clinical engineer 12 (37.5)
Manager 9 (28.1)
Research scientist 7 (21.9)
Biomedical engineer 2 (6.3)
Healthcare technologist or
technician
2 (6.3)
Clinical technologist or technician 1 (3.1)
Otherb 5 (15.6)
Highest level of education
obtained
Bachelor 5 (15.6)
Masters 10 (31.1)
Doctorate 12 (37.5)
Otherc 5 (15.6)
Years of service 1–5 years 2 (6.3)
6–10 years 3 (9.4)
11–15 years 6 (18.8)
16+ years 21 (65.6)
Role in organization Healthcare technology
assessment
22 (68.8)
Healthcare technology
management
18 (56.3)
Healthcare technology research 10 (31.1)
Healthcare technology
maintenance
8 (25)
Healthcare technology innovation 7 (21.9)
Healthcare technology service 3 (9.4)
Healthcare technology sales 0 (0)
Otherd 5 (15.6)
Organization type of principal
employer
Healthcare provider – acute
hospital
8 (25)
Academic Institution – university 7 (21.9)
Non-government organization 2 (6.3)
Table 2. Continued
Characteristic Description Frequency (%)
Healthcare provider – community
care
1 (3.1)
Industry/commercial –
manufacturer
1 (3.1)
Industry/commercial – services 1 (3.1)
No response 2 (6.3)
Othere 10 (31.1)
aSome panelists responded as having more than one profession.
bOther included: medical equipment assessor (n= 1), HTA senior scientist (n= 1),
chemical engineer (n= 1), health technology assessment and physician n= 1).
cOther included: CE specialist (n= 1), engineer (n= 1); engineer with post-graduate
in health administration (n= 1), business management (n= 1); electro-mechanical
engineer from 5-year university program (n= 1).
dOther included: capital planning (n= 1), clinical engineering instructor or professor
(n= 2), health technology regulator (n= 1), healthcare technology policy and meth-
odology (n= 1).
eOther included: retired (n= 1); government (n= 3); industry trade association
(n= 1), HTA public institution (n= 1), academic/government (n= 1), regulatory
authority for medical devices (n= 1), healthcare provider in public sector (n= 2).
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Table 3. Recommendations to Address the Gaps in HTA Methods Guidelines for MDs and Delphi Survey Results
Gaps in HTA methods guidelines for medical devices Recommendations to address gaps
Median
(IQR)
No. of panelists
(%)
Product lifecycle
Timeframe to perform a complete a HTA is much reduced in the MD lifecycle compare to drugs. Spending
several months or years to conduct a HTA may result in an outdated or obsolete (e.g., a newer version of
the device is available) report.
◦ Limited evidence is available to meet the objectives of HTA
◦ The time horizon of the economic evaluation may be inaccurate
◦ Estimates of cost recovery may be inaccurate in the cost-effectiveness analyses
1. Use the available evidence to accurately estimate the cost-effective-
ness of the MD and to quantify its uncertainty. When evidence is
lacking, HTA experts could run clinical performance and usability
analysis to gather relevant insights for their analysis.
4 (4,5) 31 (96.9)
2. Use appropriate methods to assess the quality of modelling the effect
of the different types of evidence on the effectiveness and safety of
the MD.
4 (3,4) 31 (96.9)
3. Conduct sensitivity analyses in economic model to measure the
impact on the results of varying lifespans or incremental innovations.
4 (3,5) 31 (96.9)
Maintenance of the device and the characteristics of the services for the device may impact costs, efﬁcacy,
effectiveness, and safety of the MD over its lifespan.
4. Obtain additional insights about the maintenance required, and
capture maintenance impact in the HTA by using appropriate methods
of contextual inquiry. The context inquiry can include, for instance,
gather information about the service requirements in terms of pre-
ventive maintenance planning, costs, downtime and by gathering
qualitative data about the needs of the stakeholders of the service.
5 (4,5) 31 (96.9)
Instability of individual parts may impact the safety, efﬁcacy, effectiveness, user satisfaction, and costs. 5. Conduct a risk assessment by using appropriate and validated tool or
standards.
4 (4,5) 30 (93.8)
6. Conduct, when necessary, a simulation of use to empirically analyze
safety in use and deﬁne procedures of risk report, and processes to
mitigate residual risks.
4 (4,5) 30 (93.8)
Majority of HTAs focuses one technology per time and dependences of this technology with surrounding ones
are almost never considered.
7. Map the process of device use, and explicitly state the organizational
constraints, technological and structural conditions in which the trial
was performed.
5 (4,5) 31 (96.9)
8. Conduct an analytic assessment to estimate “what if” the minimum
requirements are not met.
5 (4,5) 31 (96.9)
9. Manage and ensure processes of data exchange and interoperability
of the device with hospital system and with other devices.
4 (3,5) 31 (96.9)
10. Increase stakeholders (i.e., technicians, health care providers, and
patients) awareness of interdependences and interferences among
the devices.
4 (4,5) 30 (93.8)
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Table 3. Continued
Gaps in HTA methods guidelines for medical devices Recommendations to address gaps
Median
(IQR)
No. of panelists
(%)
Clinical evaluation
Impact on the estimation of efﬁcacy, effectiveness, satisfaction in use, cost-effectiveness, service provision. 11. Use both pre-market and post-market studies to capture impact of
learning curve on outcomes. The evidence can include a risk and
usability assessment.
4 (4,5) 30 (93.8)
12. Collect and report data on the effects of learning on relevant pro-
cedural and clinical outcomes during clinical trials, both at the
physician and health care system levels.
4 (4,5) 30 (93.8)
13. Collect registry data that allow the estimation of the learning curve
based on routine use of the MD once it has been adopted in clinical
practice.
5 (4,5) 31 (96.9)
14. Explicitly state the clinicians’ experience with the speciﬁc procedure
(e.g., number of hernia repairs performed on similar patients) and
in particular with the device under assessment of a similar one
(e.g., previous version, similar device), if any.
4 (4,5) 29 (90.6)
15. Describe in detail the training and training materials for the device
use (e.g., guideline of use and service process associated to the
device use, etc.) provided to the users of the MD.
5 (4,5) 30 (93.8)
16. Use appropriate statistical methods to incorporate learning curve
corrections into the measurement of costs and relevant outcomes.
4 (4,5) 29 (90.6)
Unlike drugs, MDs can be both diagnostic and therapeutic, and they can inﬂuence the clinical decision making
process and the patient’s clinical care pathway.
17. Adopt appropriate study designs for MDs. The design can include
preliminary phases of clinical pathway mapping and qualitative
analysis to identify the most appropriated setting, comparators and
variables to be considered in a trial.
5 (4,5) 30 (93.8)
18. Reinforce the use of simulation (e.g., in silico trial) in case of
incremental innovation.
4 (4,5) 29 (90.6)
Issues in use
Same MD used by different users in different contexts may have different costs, efﬁcacy, effectiveness, and
safety, both in the short time (e.g., during the trial) and during its lifespan.
19. Use both pre-market and post-market data to capture impact of
context of use variables (i.e., user, tasks, physical and social
environment) on HTA outcomes.
5 (4,5) 30 (93.8)
20. Simulate and use appropriate statistical methods to analyze the
different types of evidence on the effectiveness and safety of the
MD.
4 (4,5) 30 (93.8)
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Table 3. Continued
Gaps in HTA methods guidelines for medical devices Recommendations to address gaps
Median
(IQR)
No. of panelists
(%)
Required training may impact costs, efﬁcacy, effectiveness, and safety of the MD. 21. Use both pre-market and post-market studies to capture impact of
learning curve on outcomes.
4 (4,5) 30 (93.8)
22. Select appropriate outcomes that reﬂect impact of the learning curve
and the setting in which the device will be operated.
5 (4,5) 29 (90.6)
23. Simulate and use appropriate statistical methods to analyze the
different types of evidence on the effectiveness and safety of the
MD.
4 (4,5) 31 (96.9)
24. Perform training simulations to help develop appropriate training
strategies for the users.
4 (4,5) 29 (90.6)
25. Use appropriate statistical methods to analyze the different types of
evidence that reﬂects the learning curve with the MD.
4 (4,5) 29 (90.6)
Costs and economic evaluations
Lack of evidence-based maintenance and service program formulation, manufacturer recommendations can be
difﬁcult to fulﬁll in budget-constrain circumstances and this can cause safety problems or affect MD
effectiveness along the whole lifecycle.
◦ Maintenance and installation procedures, and therefore their costs per each device, depend strongly on
local clinical engineering and biomedical technician availability and expertise. This change signiﬁcantly
costs across different hospitals.
26. Understand and describe explicitly in the HTA report, all the possible
maintenance, installation, and operational costs considered.
5 (4.25,5) 30 (93.8)
27. Ensure that all reasonable maintenance, installation, and ongoing
facilities costs are incorporated in the economic evaluation, or
explicitly state the hypothesis of the study conducted.
5 (4,5) 30 (93.8)
28. Describe the organizational model considered in the economic
evaluation for maintenance and installation (e.g., internal clinical
engineering service).
5 (4,5) 30 (93.8)
29. If feasible, ensure that costs arising from missed maintenance are
also considered.
4 (4,5) 30 (93.8)
Different ﬁnancial models in acquisition of the technology (e.g., leasing) – scarce use of risk sharing
agreements
30. Understand and ensure that the potential impact of ﬁnancial models
is represented in the economic evaluation.
5 (4,5) 29 (90.6)
HTA, health technology assessment; IQR, interquartile range; MD, medical device.
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process because they can identify durability and rare serious
adverse events from long-term use of the device (32). Given
the important methodological issues and contextual considera-
tions that require attention in the assessment of MDs, research
initiatives are under way to address them (18,19,31–33).
Delphi panelists also agree with focus group results that the
adoption of a medical device has a more significant impact in
an organization compared with the introduction of a new
drug therapy due to implementation consideration and mainten-
ance issues for those lasting longer than single use devices.
Furthermore, a medical device can have numerous applications
and a shorter lifecycle, and its effectiveness is impacted by the
user interaction, setting, and the learning curve to operate it
(27–29).
An important gap in HTAs identified by focus group
experts and, confirmed by panelists, is the need of methods
to estimate the impact of the learning curve related to the effect-
iveness, safety, and costs associated with the use of MDs, and
relevant evidence is also lacking. Methods for the estimation
of the learning curve are well-established, although these
have not yet been incorporated in guidelines or used to
inform postmarket data collection (34). The incorporation of
the learning curve and contextual factors into economic evalua-
tions still represent a great challenge in MD assessments (35).
In terms of risk assessment, some panelists believed that the
original manufacturers of the device should be responsible for
reporting risks, including the required maintenance, and provide
user, technical, and maintenance training to professionals
accountable for the application and maintenance of the MD.
Panelists identified value-based procurement, a process
which focuses on health system performance and patient out-
comes, and longer-term cost efficiencies, and working with sup-
pliers to identify opportunities to develop innovative products and
services (36), as a relevant forum to assess the impact of the main-
tenance required and financial models (e.g., leasing agreements)
represented in economic evaluations because an HTA would
unlikely be able to address these items in its current form.
Limitations
The interpretation and application of our study may be influ-
enced by several limitations. The survey presented a description
of each gap in the current HTA methods guidelines for medical
guidelines and proposed recommendations to address them.
Although none of the panelists requested further information
or clarifications it is uncertain how the panelists interpreted
the descriptions and the items of the survey. Some element of
complexity due to the textual presentations of gaps and asso-
ciated recommendations may also have pushed some respon-
dents to drop-out of the Delphi process. Finally, the panelists
represented a variety of perspectives, but it is not feasible to
identify all clinical and biomedical engineering perspectives
based on the number of survey respondents (n= 32).
Directions for Future Research
The recommendations put forth will help to provide a more inte-
grated and enhanced approach toMD assessments. Based on the
scores, the panelists agreedwith the proposed recommendations,
but remained uncertain on the feasibility for some of them, such
as assessing the effectiveness and safety of a medical device in
the product lifecycle based on the evidence and current statistical
methods and economic models. A more technical assessment
was proposed to evaluate the interoperability of a MD with
other devices or within a hospital system. Future research on
which proposed recommendations are more feasible for an
HTA versus which ones are more suitable for a study design or
technical assessment of medical device use is warranted.
Another follow-up study to this research initiative would be to
collaborate with HTA units at different levels in the healthcare
system to assess the feasibility of implementing these recom-
mendations based on the available data and evidence and to
adapt existing or develop new methods accordingly.
In conclusion, as the MD characteristics and functionality
differ from drug therapies, current HTA methods may not
accurately reflect the conclusions of their assessment. Our
paper presents recommendations informed by the focus group
discussions and Delphi survey responses that are aimed to
address the perceived gaps in the HTA guidelines and to
provide a more integrated and improved approach to HTAs
on MDs. They were organized into four categories: product
lifecycle, clinical evaluation, issues in use, and costs and eco-
nomic evaluation. According to the scores from the survey
responses, consensus was achieved for all recommendations
among thirty-two international panelists in one round. As
there is uncertainty on the feasibility in the implementation
on some of the recommendations, future research can involve
an evaluation on how to implement them in an assessment
based on the available data, evidence, and statistical methods,
and economic models used in HTAs.
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